AMENDMENTS TO THE CLAIMS

Claims 1-10 (Canceled)

11. (Currently amended) A method for ~~preventing or treating diseases accompanied by a decrease in bone weight in a mammal comprising~~ increasing bone breaking load and strength in ~~said~~ a mammal ~~by~~ comprising:

identifying a mammal having a need for increased bone breaking load and strength; and

administering to said mammal at least one member selected from the compound represented by Formula (1) or a multimer thereof from about 0.1 mg per day to about 20 mg per kg per day:



(1)

wherein A and B are the same or different and are independently selected from the group consisting of halogen, amino, amidino, anilinoamide, mercapto, sulfonic acid, phosphate, carboxy, hydroxy C_1-C_5 alkyl, sugar residue, -OR^1, and –$OCOR^2$;

wherein R^1 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl; and

R^2 is selected from the group consisting of C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl;

n is number of substituents A present and is a number from 0 to 5; and

m is number of substituents B present and is a number from 0 to 5.

Claims 12-18 (Canceled)

19. (Previously presented) A method for preventing cerebral apoplexy in a mammal, comprising administering to said mammal a composition comprising an effective amount of at least one member selected from the compound represented by Formula (1) or a multimer thereof from about 0.1 mg per day to about 20 mg per kg per day:



(1)

wherein A and B are the same or different and are independently selected from the group consisting of halogen, amino, amidino, anilinoamide, mercapto, sulfonic acid, phosphate, carboxy, hydroxy C_1-C_5 alkyl, sugar residue, -OR^1, and –$OCOR^2$;

wherein R^1 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl; and

R^2 is selected from the group consisting of C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl;

n is number of substituents A present and is a number from 0 to 5; and

m is number of substituents B present and is a number from 0 to 5;

wherein said composition does not contain ethanol.

20. (Currently amended) The method according to Claim 11, wherein the ~~disease accompanied by a decrease in bone weight is any of~~ mammal has a menopausal or postmenopausal diseases.

21. (Previously presented) The method according to Claim 11, wherein said compound is part of a pharmaceutical formulation.

22. (Previously presented) The method according to Claim 11, wherein said compound is part of a food product.

23. (Currently amended) The method according to Claim 11, wherein the mammal has a disease accompanied by a decrease in bone weight that is ~~a disease~~ accompanied by resorption of alveolar bone.

24. (Previously presented) The method according to Claim 23, wherein said compound is adapted for oral administration performed by a medium selected from the group consisting of dentifrice, liquid dentifrice, mouthwash, mouth spray, oral liniment, swab, and floss.

25. (Previously presented) The method according to Claim 11, wherein the compound represented by Formula (1) is obtained from at least one plant selected from the group

consisting of plants of Polygonaceae family, plants of Vitaceae family, white hellebore (Veratrum album), mulberry, and peanut.

26. (Previously presented) The method according to Claim 19, wherein said compound is part of a pharmaceutical formulation.

27. (Previously presented) The method according to Claim 19, wherein said compound is part of a food product.

28. (Previously presented) The method according to Claim 19, wherein cerebral apoplexy is present in menopausal or post-menopausal period.

29. (Previously presented) The method according to Claim 19, wherein the compound represented by Formula (1) is obtained from at least one plant selected from the group consisting of plants of Polygonaceae family, plants of Vitaceae family, white hellebore (Veratrum album), mulberry, and peanut.